euro-obesity-euro-vaccines-2018-tracks

5 / 20

Page 19
Note:
alliedacademies
J u n e 2 8 - 2 9 , 2 0 1 8 | A m s t e r d a m , N e t h e r l a n d s
Joint Event on
OBESITY AND WEIGHT MANAGEMENT
VACCINES AND IMMUNOLOGY
&
International Conference on
International Conference on
Asian Journal of Biomedical and Pharmaceutical Sciences | Volume 8 ISSN: 2249-622X
NANOPARTICLES, AS ANTIGEN
DELIVERY SYSTEM OF ANTIGENS,
FOR A NASAL VACCINE AGAINST
TOXOPLASMOSIS
Didier Betbeder
University Lille 2, France
Nanoparticles can act as adjuvant as they are able to deliver antigens
to immune cells, therefore increasing their immunogenicity. A better
knowledgeof themechanismsof interactionwith thebiological fluidsandcells
is necessary to fully understand their potential as delivery systems. Most of
pathogens access to human body through mucosal, therefore it is interesting
to mimic infection to elicit a protective immunity. In this presentation we
will describe the mechanisms of interaction of nanoparticles with airway
mucosa cells and their ability to deliver antigens within cells. Furthermore,
their interest in term of antigen formulation, stability and efficacy against
Toxoplasma gondii infection will be presented.
Pr Didier Betbeder has 25 years of experience
in drug delivery using colloids, ranging from
basic research to clinical studies. Working with
the World Health Organisation he obtained his
PhD in 1988 on drug targeting to treat sleep-
ing sickness, before spending two years as a
post-doctoral fellow at the University of War-
wick (England). He was then engaged by Bio-
Europe, a company specialising in biocatalysis,
before joining Biovector Therapeutics (France)
as Research director from 1992 – 2001. He is
Professor at the University of Artois and Lille 2
since 2001, his research focusing on the devel-
opment of innovative nanoparticles based on
polysaccharide and phospholipid assemblies.
He developed from research to clinical devel-
opment a technology based on polysaccharide
nanoparticles supporting a phospholipid bi-lay-
er, these nanoparticles were found to have a
strong mucosal residence and good candidates
for vaccine applications.
BIOGRAPHY
Didier Betbeder, Asian J Biomed Pharmaceut Sci 2018, Volume 8 | DOI: 10.4066/2249-622X-C1-002